# Autism Medication Interaction & Cross-Reference Clinical Matrix (2026) | CĒD Clinic > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/advisor/pediatric-adolescent/autism/medication-interactions/ > **Published:** 2026-09-28T17:41:18-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:12:39-04:00 > **Clinical Summary:** CĒD CLINIC Pediatric Autism 🧭 Visual Navigator Symptom Hubs ⚡ Aggression & Meltdowns Acute autonomic de-escalation & safety 🌙 Sleep & Circadian Insomnia Sleep latency, night waking & melatonin 💬 Non-Verbal & Frustration Alternative communication & pain proxies 🍎 Gut-Brain Axis & ARFID Motility, sensory aversions & visceral discomfort 🌪️ Sensory Overload & Stimming Regulating […] --- [CĒD CLINIC Pediatric Autism](https://cedclinic.com/advisor/pediatric-adolescent/autism/) [🧭 Visual Navigator](https://cedclinic.com/advisor/pediatric-adolescent/visual-navigator/) [⚡ Aggression & Meltdowns Acute autonomic de-escalation & safety](https://cedclinic.com/advisor/pediatric-adolescent/autism/aggression-and-meltdowns/) [🌙 Sleep & Circadian Insomnia Sleep latency, night waking & melatonin](https://cedclinic.com/advisor/pediatric-adolescent/autism/sleep-and-insomnia/) [💬 Non-Verbal & Frustration Alternative communication & pain proxies](https://cedclinic.com/advisor/pediatric-adolescent/autism/non-verbal-communication-and-frustration/) [🍎 Gut-Brain Axis & ARFID Motility, sensory aversions & visceral discomfort](https://cedclinic.com/advisor/pediatric-adolescent/autism/gut-brain-axis-and-feeding/) [🌪️ Sensory Overload & Stimming Regulating striatal hyper-reactivity](https://cedclinic.com/advisor/pediatric-adolescent/complex-behavior/) [🧬 Rare Neurogenetic Syndromes Fragile X, SYNGAP1, Rett & CDKL5](https://cedclinic.com/advisor/pediatric-adolescent/genetic-syndromes/) [🌿 Oncology & Palliative Care Pediatric complex care & symptom support](https://cedclinic.com/advisor/pediatric-adolescent/oncology-palliative/) [🎒 Puberty & School Transition Hormonal shifts, IEPs & adolescent care](https://cedclinic.com/advisor/pediatric-adolescent/autism/puberty-adolescence-and-crisis/) Triage & Symptom Screeners [⚖️ Meltdown vs. Seizure Triage Differentiate behavioral storms from subclinical seizures](https://cedclinic.com/advisor/pediatric-adolescent/autism/meltdown-shutdown-seizure-triage/) [🩹 Silent Pain Proxy Checklist Identify hidden physical pain in non-verbal children](https://cedclinic.com/advisor/pediatric-adolescent/autism/silent-pain-somatic-proxy-checklist/) [🦠 Gut vs. Behavior Screener Connect GI reflux/motility to sudden agitation](https://cedclinic.com/advisor/pediatric-adolescent/autism/gut-vs-behavior-screener/) [⚠️ Illness vs. Behavior (PANS) Distinguish infectious flares from neurobehavior](https://cedclinic.com/advisor/pediatric-adolescent/autism/illness-vs-behavior-screener/) [🧠 PDA vs. ODD Screener Demand avoidance rooted in nervous system threat](https://cedclinic.com/advisor/pediatric-adolescent/autism/pda-autism-vs-odd-nervous-system-screener/) Protocols & Care Plans [💊 Medication Interaction Screen CYP450 metabolism & cross-taper safety](https://cedclinic.com/advisor/pediatric-adolescent/autism/medication-interactions/) [🎒 IEP & 504 Accommodations Clinical letter templates for schools](https://cedclinic.com/advisor/pediatric-adolescent/autism/autism-school-iep-504-medical-accommodation-guide/) [🚪 Elopement & Safety Plan First-responder emergency profiles](https://cedclinic.com/advisor/pediatric-adolescent/autism/autism-elopement-wandering-first-responder-safety-plan/) [🕒 Decompression Builder Prevent the 4:00 PM post-school crash](https://cedclinic.com/advisor/pediatric-adolescent/autism/after-school-decompression-builder/) [🛋️ Caregiver Sanctuary Parent nervous system recovery & cortisol balance](https://cedclinic.com/advisor/pediatric-adolescent/autism/caregiver-sanctuary/) [⚖️ Pediatrician & DCF Guide Navigating Mandated Reporting & State Agencies](https://cedclinic.com/advisor/pediatric-adolescent/autism/pediatrician-and-dcf-guide/) [🏛️ Massachusetts Legal Guide Two-physician certification & legal protections](https://cedclinic.com/advisor/pediatric-adolescent/autism/massachusetts-pediatric-medical-cannabis-guide/) [📋 Doctor Discussion Script How to speak with hesitant neurologists & pediatricians](https://cedclinic.com/advisor/pediatric-adolescent/autism/doctor-discussion-guide/) [📁 Clinical Appointment Passport Organized dossier for medical teams](https://cedclinic.com/advisor/pediatric-adolescent/autism/pediatric-autism-clinical-passport-appointment-binder/) [🔬 The Science of Anandamide Endocannabinoid deficiency research in autism](https://cedclinic.com/advisor/pediatric-adolescent/autism/anandamide-and-cannabinoids/) [📅 Book Consult](https://cedclinic.com/book/) [🧭 Open Visual Symptom Navigator](https://cedclinic.com/advisor/pediatric-adolescent/visual-navigator/) Symptom Hubs [⚡ Aggression & Meltdowns](https://cedclinic.com/advisor/pediatric-adolescent/autism/aggression-and-meltdowns/) [🌙 Sleep & Insomnia](https://cedclinic.com/advisor/pediatric-adolescent/autism/sleep-and-insomnia/) [💬 Non-Verbal & Frustration](https://cedclinic.com/advisor/pediatric-adolescent/autism/non-verbal-communication-and-frustration/) [🍎 Gut-Brain & Feeding](https://cedclinic.com/advisor/pediatric-adolescent/autism/gut-brain-axis-and-feeding/) [🌪️ Sensory Overload & Stimming](https://cedclinic.com/advisor/pediatric-adolescent/complex-behavior/) [🧬 Rare Neurogenetic Syndromes](https://cedclinic.com/advisor/pediatric-adolescent/genetic-syndromes/) [🌿 Oncology & Palliative Care](https://cedclinic.com/advisor/pediatric-adolescent/oncology-palliative/) [🎒 Puberty & School Transition](https://cedclinic.com/advisor/pediatric-adolescent/autism/puberty-adolescence-and-crisis/) Clinical Screeners & Tools [⚖️ Meltdown vs. Seizure Triage](https://cedclinic.com/advisor/pediatric-adolescent/autism/meltdown-shutdown-seizure-triage/) [🩹 Silent Pain Proxy Checklist](https://cedclinic.com/advisor/pediatric-adolescent/autism/silent-pain-somatic-proxy-checklist/) [🦠 Gut vs. Behavior Screener](https://cedclinic.com/advisor/pediatric-adolescent/autism/gut-vs-behavior-screener/) [⚠️ Illness vs. Behavior Screener](https://cedclinic.com/advisor/pediatric-adolescent/autism/illness-vs-behavior-screener/) [💊 Medication Interactions](https://cedclinic.com/advisor/pediatric-adolescent/autism/medication-interactions/) [🎒 School IEP & 504 Accommodations](https://cedclinic.com/advisor/pediatric-adolescent/autism/autism-school-iep-504-medical-accommodation-guide/) [🚪 Elopement & Safety Plan](https://cedclinic.com/advisor/pediatric-adolescent/autism/autism-elopement-wandering-first-responder-safety-plan/) [🛋️ Caregiver Sanctuary](https://cedclinic.com/advisor/pediatric-adolescent/autism/caregiver-sanctuary/) Family & Legal Guides [⚖️ Pediatrician & DCF Guide](https://cedclinic.com/advisor/pediatric-adolescent/autism/pediatrician-and-dcf-guide/) [🏛️ Massachusetts Legal Guide](https://cedclinic.com/advisor/pediatric-adolescent/autism/massachusetts-pediatric-medical-cannabis-guide/) [📋 Doctor Discussion Script](https://cedclinic.com/advisor/pediatric-adolescent/autism/doctor-discussion-guide/) [📁 Clinical Passport Binder](https://cedclinic.com/advisor/pediatric-adolescent/autism/pediatric-autism-clinical-passport-appointment-binder/) [📅 Book Consultation with Dr. Caplan](https://cedclinic.com/book/) [Home](https://cedclinic.com/) › [Pediatrics](https://cedclinic.com/pediatrics/) › [Autism Clinical Hub](https://cedclinic.com/advisor/pediatric-adolescent/autism/) › Medication Interactions Pharmacology & Safety Reference • 2026 Edition Table of Contents - [Autism Medication Interaction & Cross-Reference Clinical Matrix](#Autism_Medication_Interaction_Cross-Reference_Clinical_Matrix)[Clobazam (Onfi®)](#Clobazam_Onfi) - [Valproic Acid / Divalproex (Depakote®)](#Valproic_Acid_Divalproex_Depakote) - [Risperidone (Risperdal®)](#Risperidone_Risperdal) - [Aripiprazole (Abilify®)](#Aripiprazole_Abilify) - [Guanfacine (Tenex® / Intuniv®)](#Guanfacine_Tenex_Intuniv) - [Clonidine (Catapres® / Kapvay®)](#Clonidine_Catapres_Kapvay) - [Stimulants: Methylphenidate & Amphetamines (Concerta®, Vyvanse®, Adderall®)](#Stimulants_Methylphenidate_Amphetamines_Concerta_Vyvanse_Adderall) - [SSRIs: Sertraline & Fluoxetine (Zoloft®, Prozac®)](#SSRIs_Sertraline_Fluoxetine_Zoloft_Prozac) - [Melatonin (Endogenous Neurohormone / Supplement)](#Melatonin_Endogenous_Neurohormone_Supplement) - [Lamotrigine (Lamictal®)](#Lamotrigine_Lamictal) - [Schedule a Clinical Consultation with Dr. Benjamin Caplan](#Schedule_a_Clinical_Consultation_with_Dr_Benjamin_Caplan) - [The Complete CĒD Clinic Pediatric Autism Clinical Suite](#The_Complete_CED_Clinic_Pediatric_Autism_Clinical_Suite) - [Scientific Citations & Pharmacokinetic References](#Scientific_Citations_Pharmacokinetic_References) # Autism Medication Interaction & Cross-Reference Clinical Matrix A comprehensive, evidence-grounded pharmacokinetic cross-reference for families and physicians. Details CYP450 enzyme pathways, competitive hepatic inhibition, dosing buffers, and clinical laboratory monitoring across 10 major autism medication classes. **Clinical Reviewer:** Dr. Benjamin Caplan, MD (CĒD Clinic) • **Primary Pharmacokinetics:** CYP3A4, CYP2C19, CYP2D6 & Hepatic Clearance **Tier 1: High Interaction Risk** Potent enzymatic competition or cumulative hepatic load. Requires proactive dose adjustments, blood level monitoring, and strict physician supervision. **Tier 2: Moderate / Buffer Required** Enzymatic overlap (CYP3A4/CYP2D6) or additive physiological effects (sedation/blood pressure). Managed safely with a 2-hour spacing buffer and conservative titration. **Tier 3: Low Kinetic Risk / Synergistic** Minimal direct CYP competition. Primary interactions are therapeutic or receptor-level (e.g. GABAergic, serotonergic, circadian). ### Clobazam (Onfi®) 1,5-Benzodiazepine • Anticonvulsant Tier 1 • High Interaction Primary Hepatic Pathway CYP3A4 & CYP2C19 Cannabinoid Kinetic Impact CYP2C19 Inhibition (Increases Active Metabolite) Mandatory Buffer Window Minimum 2 to 3 Hours **Pharmacokinetic Mechanism:** CBD is a potent competitive inhibitor of CYP2C19 [1, 2]. Clobazam is metabolized by CYP3A4 into its active metabolite, *N-desmethylclobazam (N-CLB)*, which is then cleared via CYP2C19. When CBD is introduced, N-CLB clearance is blocked, resulting in up to a 3-fold elevation in active metabolite serum levels. This frequently induces marked somnolence, drooling, or ataxia without changing the parent clobazam levels. **Clinical Monitoring:** If significant daytime sedation emerges, the prescribing neurologist can typically reduce the clobazam dose by 30% to 50% while maintaining or improving seizure and behavioral control [1]. Check serum clobazam/N-CLB levels if somnolence occurs. ### Valproic Acid / Divalproex (Depakote®) Broad-Spectrum Anticonvulsant • Mood Stabilizer Tier 1 • High Interaction Primary Hepatic Pathway Glucuronidation (UGT) & Mitochondrial Beta-Oxidation Cannabinoid Kinetic Impact Additive Hepatocellular Burden Mandatory Buffer Window Minimum 2 Hours **Pharmacokinetic Mechanism:** Co-administration of high-dose broad-spectrum CBD with valproate creates an additive risk of elevated hepatic transaminases (ALT/AST > 3x upper limit of normal) [3]. While not directly mediated by CYP enzymes, the simultaneous burden on hepatic metabolic clearance requires vigilant biochemical oversight. **Clinical Monitoring:** Mandatory baseline Liver Function Tests (LFTs) prior to cannabinoid initiation. Repeat hepatic transaminases at 1, 3, and 6 months. Discontinue or titrate CBD downward if transaminases exceed 3x normal limits [3]. ### Risperidone (Risperdal®) Second-Generation Atypical Antipsychotic (FDA Approved for ASD Irritability) Tier 2 • Moderate Interaction Primary Hepatic Pathway CYP2D6 & CYP3A4 Cannabinoid Kinetic Impact Mild-to-Moderate CYP2D6/3A4 Competitive Inhibition Mandatory Buffer Window Minimum 2 Hours **Pharmacokinetic Mechanism:** Risperidone is converted by CYP2D6 into its active moiety, 9-hydroxyrisperidone (paliperidone), with secondary metabolism via CYP3A4 [4]. CBD exerts mild inhibitory effects on both enzymes. Co-administration can subtly elevate circulating active drug concentrations, potentially amplifying sedation, appetite stimulation, or extrapyramidal symptoms. **Clinical Monitoring:** Observe for accentuated lethargy, motor restlessness (akathisia), or rapid weight gain. Monitor fasting prolactin levels and metabolic panels every 6 months. Many patients successfully utilize cannabinoids as a dose-sparing agent under psychiatric care [5]. ### Aripiprazole (Abilify®) Atypical Antipsychotic / Dopamine D2 Partial Agonist Tier 2 • Moderate Interaction Primary Hepatic Pathway CYP2D6 & CYP3A4 Cannabinoid Kinetic Impact CYP3A4 Competitive Inhibition Mandatory Buffer Window Minimum 2 Hours **Pharmacokinetic Mechanism:** Aripiprazole undergoes extensive dehydrogenation and hydroxylation via CYP3A4 and CYP2D6. CBD and delta-9-THC are substrates and competitive inhibitors of CYP3A4 [4, 6]. Concomitant administration may prolong elimination half-life and raise steady-state concentrations. **Clinical Monitoring:** Track daytime alertness, impulse control changes, and involuntary muscle twitches. If excessive sedation occurs, the psychiatrist may consider a conservative dosage reduction. ### Guanfacine (Tenex® / Intuniv®) Selective Alpha-2A Adrenergic Receptor Agonist Tier 2 • Moderate Interaction Primary Hepatic Pathway CYP3A4 / CYP3A5 Cannabinoid Kinetic Impact Additive Hypotensive & Sedative Effects Mandatory Buffer Window Minimum 2 Hours **Pharmacokinetic Mechanism:** Guanfacine is primarily cleared by CYP3A4. CBD inhibition can moderately elevate guanfacine plasma levels [4]. More significantly, both alpha-2 agonists and phytocannabinoids reduce sympathetic autonomic tone, creating potential synergistic blood pressure and heart rate lowering. **Clinical Monitoring:** Check resting blood pressure and pulse periodically. Watch for dizziness upon standing (orthostatic hypotension), pallor, or excessive afternoon sluggishness. ### Clonidine (Catapres® / Kapvay®) Centrally Acting Alpha-2 Adrenergic Agonist Tier 2 • Moderate Interaction Primary Hepatic Pathway CYP2D6 & Renal Excretion (50%) Cannabinoid Kinetic Impact Additive CNS Depression & Bradycardia Mandatory Buffer Window Minimum 2 Hours **Pharmacokinetic Mechanism:** Approximately 50% of clonidine is metabolized by the liver, with the remainder excreted unchanged by the kidneys. The primary interaction is pharmacodynamic rather than pharmacokinetic: both agents dampen central locus coeruleus noradrenergic firing, enhancing sleepiness. **Clinical Monitoring:** Avoid giving bedtime cannabinoids simultaneously with nighttime clonidine. Space by 90-120 minutes to avoid precipitous dips in nocturnal blood pressure or heavy morning grogginess. ### Stimulants: Methylphenidate & Amphetamines (Concerta®, Vyvanse®, Adderall®) CNS Stimulants • Dopamine/Norepinephrine Reuptake Inhibitors Tier 3 • Low Kinetic / Autonomic Balance Primary Hepatic Pathway CES1 (Methylphenidate) / CYP2D6 (Amphetamines) Cannabinoid Kinetic Impact Minimal Kinetic Overlap; Counterbalances Agitation Mandatory Buffer Window Standard 2 Hours **Pharmacokinetic Mechanism:** Methylphenidate is deactivated primarily by carboxylesterase 1 (CES1), avoiding major CYP450 competition entirely. Amphetamines involve CYP2D6. Pharmacodynamically, broad-spectrum CBD and CBG often soften stimulant-induced rebound irritability, appetite suppression, and evening insomnia without neutralizing daytime executive focus [7]. **Clinical Monitoring:** Monitor resting pulse. Unmonitored or elevated delta-9-THC can cause tachycardia which may compound stimulant cardiovascular load. Keep THC at micro-doses (<0.5-1 mg) when stimulants are active. ### SSRIs: Sertraline & Fluoxetine (Zoloft®, Prozac®) Selective Serotonin Reuptake Inhibitors Tier 2 • Moderate Interaction Primary Hepatic Pathway CYP2C19 (Sertraline) / CYP2D6 (Fluoxetine) Cannabinoid Kinetic Impact CYP2C19 Inhibition; 5-HT1A Receptor Synergy Mandatory Buffer Window Minimum 2 Hours **Pharmacokinetic Mechanism:** Sertraline clearance depends heavily on CYP2C19; CBD co-administration can modestly raise sertraline levels [2]. Fluoxetine itself is a strong CYP2D6 inhibitor. At the receptor level, CBD acts as an allosteric modulator and partial agonist at the serotonin 5-HT1A receptor, producing harmonious anxiolytic signaling without precipitating Serotonin Syndrome at physiological doses [8]. **Clinical Monitoring:** Watch for signs of excessive serotonergic activation (unusual hyperactivity, diarrhea, shivering, or nocturnal teeth grinding/bruxism). ### Melatonin (Endogenous Neurohormone / Supplement) Circadian Phase Regulator • MT1/MT2 Receptor Agonist Tier 3 • Low Kinetic / Synergistic Primary Hepatic Pathway CYP1A2 (First-Pass Clearance) Cannabinoid Kinetic Impact Synergistic Circadian Restoration Mandatory Buffer Window None (Compatible Timing) **Pharmacokinetic Mechanism:** Melatonin is metabolized primarily by CYP1A2 with negligible direct competition from typical CBD doses. In autistic children who suffer from "The Melatonin Paradox" (falling asleep quickly but waking at 2:00 AM wired and hyperactive), full-spectrum cannabinoids (CBD/CBN/micro-THC) target adenosine and CB1 sleep maintenance pathways, providing the sleep continuity that supplemental melatonin cannot [9]. **Clinical Monitoring:** Often allows parents to reduce mega-dose melatonin (which frequently causes vivid nightmares or morning grogginess) down to physiological levels (0.5 - 1 mg). ### Lamotrigine (Lamictal®) Voltage-Gated Sodium Channel Antagonist • Anticonvulsant Tier 3 • Low Kinetic Overlap Primary Hepatic Pathway Hepatic Glucuronidation (UGT1A4) Cannabinoid Kinetic Impact Minimal Direct Interference Mandatory Buffer Window Standard 2 Hours **Pharmacokinetic Mechanism:** Lamotrigine is cleared almost exclusively through glucuronidation (UGT enzymes) rather than CYP450 oxidation [1]. Clinical trials in pediatric epilepsy demonstrate minimal alterations in lamotrigine serum concentrations when adjunctive CBD is introduced, making it one of the most pharmacokinetically stable co-therapies. **Clinical Monitoring:** Routine clinical surveillance. As with any neurological therapy, monitor for skin rashes or subjective changes in cognitive clarity. Physician Consultation ### Schedule a Clinical Consultation with Dr. Benjamin Caplan Every child's neurobiology is unique. At CĒD Clinic, we provide comprehensive pediatric and adolescent clinical evaluations, review medication regimens, and design safe, physician-supervised cannabinoid protocols. [Book an Appointment →](https://cedclinic.com/book/) ### The Complete CĒD Clinic Pediatric Autism Clinical Suite Every medication adjustment requires informed clinical guidance. Explore our connected clinical tools and educational pillars: [🩺 Doctor Discussion Guide Printable scripts, clinical letter templates, and appointment strategies for your child's doctors.](https://cedclinic.com/advisor/pediatric-adolescent/autism/doctor-discussion-guide/) [📉 Safe Deprescribing Roadmap Part 6 of our blog series: Managing rebound neuro-agitation and safely tapering atypical antipsychotics.](https://cedclinic.com/autism-medication-weaning-deprescribing-roadmap/) [📊 What We're Learning Gallery Master developmental infographic and clinical lessons distilled from hundreds of patient families.](https://cedclinic.com/advisor/pediatric-adolescent/autism/what-were-learning/) [👶 Main Pediatric Practice Comprehensive pediatric cannabis medicine, scheduling consultations, and state registry support.](https://cedclinic.com/pediatrics/) ### Scientific Citations & Pharmacokinetic References - Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP. *Interactions between cannabidiol and commonly used antiepileptic drugs.* **Epilepsia**. 2017;58(9):1586-1592. [PubMed PMID: 28782097](https://pubmed.ncbi.nlm.nih.gov/28782097/). - Geffrey AL, Pollack SF, Bruno PL, Thiele EA. *Drug-drug interaction between clobazam and cannabidiol in children for refractory epilepsy.* **Epilepsia**. 2015;56(8):1246-1251. [PubMed PMID: 26114620](https://pubmed.ncbi.nlm.nih.gov/26114620/). - Devinsky O, Cross JH, Laux L, et al. *Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.* **New England Journal of Medicine**. 2017;376(21):2011-2020. [PubMed PMID: 28538134](https://pubmed.ncbi.nlm.nih.gov/28538134/). - Qian K, Zheng X, He J, et al. *Involvement of Cytochrome P450 Enzymes in Cannabidiol Metabolism and its Drug Interaction Profile.* **Frontiers in Pharmacology**. 2019;10:1447. [PubMed PMID: 31866870](https://pubmed.ncbi.nlm.nih.gov/31866870/). - Aran A, Cassuto H, Lubotzky A, Hevroni N, Greenfield M. *Brief Report: Cannabidiol-Rich Cannabis in Children with [Autism Spectrum Disorder](https://cedclinic.com/cbd-gummies-autism-symptoms-clinical/) and Severe Behavioral Problems—A Retrospective Feasibility Study.* **Journal of Autism and Developmental Disorders**. 2019;49(3):1284-1288. [PubMed PMID: 30382443](https://pubmed.ncbi.nlm.nih.gov/30382443/). - Iffland K, Grotenhermen F. *An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies.* **Cannabis and Cannabinoid Research**. 2017;2(1):139–154. [PubMed PMID: 28861514](https://pubmed.ncbi.nlm.nih.gov/28861514/). - Bar-Lev Schleider L, Mechoulam R, Saban N, Meiri G, Novack V. *Real life Experience of [Medical Cannabis](https://cedclinic.com/cbd-gummies-for-sexual-enhancement-evidence/) Treatment in Autism: Analysis of Safety and Efficacy.* **Scientific Reports (Nature)**. 2019;9(1):200. [PubMed PMID: 30655581](https://pubmed.ncbi.nlm.nih.gov/30655581/). - Russo EB. *Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.* **British Journal of Pharmacology**. 2011;163(7):1344-1364. [PubMed PMID: 21749363](https://pubmed.ncbi.nlm.nih.gov/21749363/). - Pretzsch CM, Freyberg J, Voinescu B, et al. *Call for clinical trials of cannabinoids in autism: A qualitative systemic review and neurobiological rationale.* **Neuropsychopharmacology**. 2019;44(8):1398–1405. [PubMed PMID: 30755716](https://pubmed.ncbi.nlm.nih.gov/30755716/). --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).